Administrative Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma
管理核心:IDEAL 影响疫苗反应、呼吸道传染病和哮喘的易感性
基本信息
- 批准号:10435036
- 负责人:
- 金额:$ 12.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-03-10 至 2027-02-28
- 项目状态:未结题
- 来源:
- 关键词:AdherenceAsthmaCellsChildhoodClinicalCommunicable DiseasesCommunicationComplementConflict (Psychology)DataDevelopmentDissectionEnsureEpigenetic ProcessFundingGeographyGoalsHumanImmuneImmune responseImmunologyIn VitroInfantInfrastructureInstitutesIntellectual PropertyInternationalLeadershipLifeMediatingMolecularOutcomePRTN3 genePredispositionProcessProgress ReportsProperty RightsProteomicsRecommendationResearch PersonnelResearch Project GrantsShapesStructureSystems BiologyTechnologyTeleconferencesTimeTimeLineUnited States National Institutes of HealthVaccinesWorkconflict resolutiondata managementdesignimprovedin silicointer-institutionalmaterial transfer agreementmeetingsprogramsrespiratorysymposiumsynergismtranscriptomicsvaccine responsevaccinologywork-study
项目摘要
PROJECT SUMMARY: IDEAL Administrative Core
Our overall proposal will investigate immune development in early life (IDEAL) to identify IDEAL endotypes
that correspond to key clinical outcomes in childhood, including vaccine response, respiratory infectious
disease and asthma. We will accomplish this goal through three distinct yet integrated studies that follow
complementary approaches via cutting-edge in silico (project 1, PR1), epigenetic (PR2), and in vitro (PR3)
research projects. Given the scientific scope, complexity, and geographic range of the proposed work, the
study IDEAL Administrative Core (AC) will be crucial to optimize the quality and impact of the proposed
studies and to ensure timely provision of projected deliverables. The goal of the IDEAL-AC is to institute
streamlined processes which facilitate productive interactions among investigators from each IDEAL Project
and Core. We will achieve this goal by pursuing the following Specific Aims (SAs):
SA1. Provide infrastructure for administrative leadership aimed at building an interactive and
collaborative working team resulting in maximal project synergy.
SA2. Facilitate and promote communication and interactions amongst the Project and Core Leads
by conducting regular teleconferences/face-to-face meetings, annual meetings, as well as
seminars/symposia focused on the IDEAL project.
SA3. Manage and optimize communication within our IDEAL team and between our team, the
other NIH supported IDEAL teams and the IDEAL Steering Committee.
SA4. Resolve potential conflicts that might arise within and outside of our IDEAL project by
implementing recommendations of the Conflicts Resolution Group (CRG).
SA5. Provide fiscal, regulatory and scientific oversight, review and consolidate yearly progress
reports sent to the NIH.
SA6. Protect intellectual property rights of our investigators and execute material transfer
agreements.
SA7. Implement the data management/sharing plan among investigators within and outside of our
IDEAL team.
Overall, the IDEAL AC will ensure appropriate stewardship of NIH funds and maintain adherence to
project timelines, all with the goal to optimize and amplify the scientific impact of the proposed studies.
项目总结:理想的行政核心
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
OFER LEVY其他文献
OFER LEVY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('OFER LEVY', 18)}}的其他基金
Immune development in early life (IDEAL) shapes vaccine response, respiratory infectious diseaseand asthma
生命早期的免疫发育 (IDEAL) 影响疫苗反应、呼吸道传染病和哮喘
- 批准号:
10435035 - 财政年份:2022
- 资助金额:
$ 12.39万 - 项目类别:
Project 3: In vitro modeling to define mechanisms of childhood vaccine response, susceptibility to respiratory infectious disease and asthma
项目 3:体外建模以确定儿童疫苗反应、呼吸道传染病和哮喘易感性机制
- 批准号:
10589826 - 财政年份:2022
- 资助金额:
$ 12.39万 - 项目类别:
Project 3: In vitro modeling to define mechanisms of childhood vaccine response, susceptibility to respiratory infectious disease and asthma
项目 3:体外建模以确定儿童疫苗反应、呼吸道传染病和哮喘易感性机制
- 批准号:
10435043 - 财政年份:2022
- 资助金额:
$ 12.39万 - 项目类别:
Immune development in early life (IDEAL) shapes vaccine response, respiratory infectious diseaseand asthma
生命早期的免疫发育 (IDEAL) 影响疫苗反应、呼吸道传染病和哮喘
- 批准号:
10589800 - 财政年份:2022
- 资助金额:
$ 12.39万 - 项目类别:
Administrative Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma
管理核心:IDEAL 影响疫苗反应、呼吸道传染病和哮喘的易感性
- 批准号:
10589801 - 财政年份:2022
- 资助金额:
$ 12.39万 - 项目类别:
IMPACC convalescent data collection, including Patient Reported Outcomes (PROs) and home visit sampling
IMPACC 恢复期数据收集,包括患者报告结果 (PRO) 和家访抽样
- 批准号:
10290547 - 财政年份:2021
- 资助金额:
$ 12.39万 - 项目类别:
IMPACC convalescent data collection, including Patient Reported Outcomes (PROs) and home visit sampling
IMPACC 恢复期数据收集,包括患者报告结果 (PRO) 和家访抽样
- 批准号:
10205742 - 财政年份:2021
- 资助金额:
$ 12.39万 - 项目类别:
Newborn cohorts to discover and validate biomarkers of neonatal vaccine immunogenicity
新生儿队列发现和验证新生儿疫苗免疫原性的生物标志物
- 批准号:
10323182 - 财政年份:2020
- 资助金额:
$ 12.39万 - 项目类别:
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity
识别新生儿疫苗免疫原性生物标志物的系统生物学
- 批准号:
10221106 - 财政年份:2020
- 资助金额:
$ 12.39万 - 项目类别:
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity
识别新生儿疫苗免疫原性生物标志物的系统生物学
- 批准号:
10265669 - 财政年份:2020
- 资助金额:
$ 12.39万 - 项目类别:
相似海外基金
Lung resident Treg suppression of Th2 resident memory T cells in allergic asthma
过敏性哮喘中肺常驻 Treg 对 Th2 常驻记忆 T 细胞的抑制
- 批准号:
10664599 - 财政年份:2023
- 资助金额:
$ 12.39万 - 项目类别:
MICA: Interrogating the functional impact of novel asthma genetic variants using genomics and inducible pluripotent stem cell-derived epithelial cells
MICA:利用基因组学和诱导多能干细胞衍生的上皮细胞探讨新型哮喘遗传变异的功能影响
- 批准号:
MR/X000974/1 - 财政年份:2023
- 资助金额:
$ 12.39万 - 项目类别:
Fellowship
Mucosal Associated Invariant T cells in the Obese-asthma endotype
肥胖哮喘内型中的粘膜相关不变 T 细胞
- 批准号:
10607523 - 财政年份:2023
- 资助金额:
$ 12.39万 - 项目类别:
Allergen-specific lung-resident Tregs in asthma: Targetable suppressors of resident memory Th2 cells
哮喘中过敏原特异性肺常驻 Tregs:常驻记忆 Th2 细胞的靶向抑制因子
- 批准号:
10563192 - 财政年份:2022
- 资助金额:
$ 12.39万 - 项目类别:
Defining the development of tissue-resident memory Th2 cells in allergic asthma
定义过敏性哮喘中组织驻留记忆 Th2 细胞的发育
- 批准号:
10501568 - 财政年份:2022
- 资助金额:
$ 12.39万 - 项目类别:
Break Down Barriers: Respiratory epithelial cells as modulators of dendritic cells during the pathogen associated allergic sensitization and acute asthma exacerbation
打破障碍:在病原体相关的过敏致敏和哮喘急性发作期间,呼吸道上皮细胞作为树突状细胞的调节剂
- 批准号:
504226880 - 财政年份:2022
- 资助金额:
$ 12.39万 - 项目类别:
Research Grants
CD4+T Cells, Alarmins and Human Airway Smooth Muscle Function in Asthma
CD4 T 细胞、警报素和哮喘患者气道平滑肌功能
- 批准号:
461568 - 财政年份:2022
- 资助金额:
$ 12.39万 - 项目类别:
Operating Grants
Defining the development of tissue-resident memory Th2 cells in allergic asthma
定义过敏性哮喘中组织驻留记忆 Th2 细胞的发育
- 批准号:
10670871 - 财政年份:2022
- 资助金额:
$ 12.39万 - 项目类别:
Transcriptional Responses to Wildfire Pollution in Airway Epithelial Cells Identify Genetic Risk Factors and Mechanisms of Asthma Exacerbations
气道上皮细胞对野火污染的转录反应确定了哮喘恶化的遗传风险因素和机制
- 批准号:
10573003 - 财政年份:2022
- 资助金额:
$ 12.39万 - 项目类别:
Allergen-specific lung-resident Tregs in asthma: Targetable suppressors of resident memory Th2 cells
哮喘中过敏原特异性肺常驻 Tregs:常驻记忆 Th2 细胞的靶向抑制因子
- 批准号:
10418189 - 财政年份:2022
- 资助金额:
$ 12.39万 - 项目类别:














{{item.name}}会员




